Breaking News

Lotte Biologics to Open Bio Plant in Incheon

By 2030 three bio plants aims to produce a total antibody medicine production capacity of 360,000 liters.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

LOTTE Biologics, a contract development and manufacturing organization (CDMO), plans to open a bio plant in Incheon Songdo. Last October, the company signed a land purchase agreement with the Incheon Free Economic Zone Authority to build a plant in Songdo International City, Incheon. By 2030, the company plans to construct three bio plants where it expects to produce a total antibody medicine production capacity of 360,000 liters. Construction on the plant, which is set to commence this year,...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters